EOLS Evolus (EOLS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001570562
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
89
13F, latest reported quarter
What the filings say about EOLS
Insiders, 180 days
-$950.0K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$950.0K
1 notice
Evolus insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Evolus, Inc. insiders sold a net $950.0K of stock across 111 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Mar 20, 2026.
- The trade is 21.0% of the 499,592 shares held after it.
- No other insider sold within 30 days.
- 89 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks MOATAZEDI DAVID sold about $950.0K of EOLS on Sep 2, 2026, the largest insider sale at the company since 2025; 89 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Mar 17, 2026.
- The trade is 0.7% of the 427,423 shares held after it.
- 1 other insider sold within 30 days.
- 89 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Avelar Rui sold about $14.8K of EOLS on Mar 20, 2026; 1 other insider sold within 30 days and 89 funds added in the latest 13F quarter.Context
- 27 earlier Form 4 trades (code P or S) here by this insider (27 sales), the last on Mar 17, 2026.
- The trade is 2.3% of the 604,700 shares held after it.
- 1 other insider sold within 30 days.
- 89 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks MOATAZEDI DAVID sold about $64.9K of EOLS on Mar 20, 2026; 1 other insider sold within 30 days and 89 funds added in the latest 13F quarter.Context
- 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Dec 22, 2025.
- The trade is 18.9% of the 618,369 shares held after it.
- 1 other insider sold within 30 days.
- 89 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks MOATAZEDI DAVID sold about $570.8K of EOLS on Mar 17, 2026; 1 other insider sold within 30 days and 89 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Dec 22, 2025.
- The trade is 7.0% of the 430,542 shares held after it.
- 1 other insider sold within 30 days.
- 89 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Avelar Rui sold about $146.7K of EOLS on Mar 17, 2026; 1 other insider sold within 30 days and 89 funds added in the latest 13F quarter.111 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$950.0K over 180 days
-$950.0K over 90 days
below 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
89 funds bought in last quarter
more than 64% of Pharma & Biotech
Revenue
+11.6% year over year
more than 61% of Pharma & Biotech
Margin
-17.4% net margin
more than 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.3% of the float short (float per yahoo 2026-10-26) · 9.3 days to cover · settled 2026-09-30
more than 66% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch EOLS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+6.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EOLS: institutional holders (13F)
13F holdings, latest reported quarter
11,204,042 sh
$77.8M
4,840,828 sh
$33.6M
3,180,324 sh
$22.1M
3,155,209 sh
$21.9M
2,630,665 sh
$18.3M
Congress trades in EOLS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EOLS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
DAVID MOATAZEDI
Filed 2026-09-02
$950.0K
EOLS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$277.9K position · as of 2026-06-30
0.9%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$2.3M position · as of 2026-06-30
0.5%
PROFUND VP PHARMACEUTICALS
$58.7K position · as of 2026-06-30
0.5%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$68.3K position · as of 2026-07-31
0.3%
Clearwater Select Equity Fund
$802.9K position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$173.5K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr. Moatazedi
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.4M
-$746.5K
$2.0M
+2%
+20%
2024
$7.0M
$4.8M
$2.1M
+70%
-9%
2023
$11.2M
$13.6M
$2.7M
+62%
-8%
2022
$3.6M
$5.8M
$1.5M
+15%
-10%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $950.0K sold by insiders over 180 days, 89 funds added last quarter, $950.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
EOLS financials
Revenue growth
+11.6%
XBRL, annual
Net margin
-17.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$316.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM EOLS
| FY Dec 2025 | $297.2M |
| FY Dec 2024 | $266.3M |
| FY Dec 2023 | $202.1M |
| FY Dec 2022 | $148.6M |
| FY Dec 2021 | $99.7M |
| Jun 2026 | $84.1M |
| Mar 2026 | $73.1M |
| Dec 2025 | $90.3M |
| Sep 2025 | $69.0M |
| Jun 2025 | $69.4M |
| Mar 2025 | $68.5M |
| Dec 2024 | $78.9M |
| Sep 2024 | $61.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-10.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM EOLS
| FY Dec 2025 | -17.4% |
| FY Dec 2024 | -18.9% |
| FY Dec 2023 | -30.5% |
| FY Dec 2022 | -50.1% |
| FY Dec 2021 | -47.0% |
| Jun 2026 | -9.6% |
| Mar 2026 | -14.6% |
| Dec 2025 | +0.1% |
| Sep 2025 | -22.8% |
| Jun 2025 | -24.7% |
| Mar 2025 | -27.6% |
| Dec 2024 | -8.6% |
| Sep 2024 | -31.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$18.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM EOLS
| FY Dec 2025 | -$45.7M |
| FY Dec 2024 | -$19.5M |
| FY Dec 2023 | -$34.5M |
| FY Dec 2022 | -$86.5M |
| FY Dec 2021 | -$33.8M |
| Jun 2026 | -$3.6M |
| Mar 2026 | -$10.4M |
| Dec 2025 | $11.3M |
| Sep 2025 | -$15.6M |
| Jun 2025 | -$25.5M |
| Mar 2025 | -$16.0M |
| Dec 2024 | $4.4M |
| Sep 2024 | -$6.0M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity EOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | 22.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 3.89x |
| FY Dec 2021 | 0.87x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 22.00x |
| Sep 2024 | 20.58x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.10x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt EOLS
| FY Dec 2025 | -0.29x |
| FY Dec 2024 | -0.15x |
| FY Dec 2023 | -0.28x |
| FY Dec 2022 | -1.18x |
| FY Dec 2021 | -0.47x |
| Jun 2026 | -0.10x |
| Mar 2026 | -0.23x |
| Dec 2025 | -0.29x |
| Sep 2025 | -0.34x |
| Jun 2025 | -0.28x |
| Mar 2025 | -0.19x |
| Dec 2024 | -0.15x |
| Sep 2024 | -0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity EOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -148.3% |
| FY Dec 2021 | -1,050% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -18,730% |
| Mar 2025 | -949.5% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets EOLS
| FY Dec 2025 | -22.5% |
| FY Dec 2024 | -23.9% |
| FY Dec 2023 | -33.6% |
| FY Dec 2022 | -34.2% |
| FY Dec 2021 | -20.1% |
| Jun 2026 | -14.4% |
| Mar 2026 | -20.0% |
| Dec 2025 | -22.5% |
| Sep 2025 | -26.1% |
| Jun 2025 | -26.8% |
| Mar 2025 | -25.6% |
| Dec 2024 | -23.9% |
| Sep 2024 | -27.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital EOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-11.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed EOLS
| FY Dec 2025 | -20.4% |
| FY Dec 2024 | -22.2% |
| FY Dec 2023 | -36.2% |
| FY Dec 2022 | -39.4% |
| FY Dec 2021 | -38.8% |
| Jun 2026 | -11.9% |
| Mar 2026 | -15.7% |
| Dec 2025 | -20.4% |
| Sep 2025 | -24.4% |
| Jun 2025 | -25.0% |
| Mar 2025 | -24.2% |
| Dec 2024 | -22.2% |
| Sep 2024 | -28.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing EOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$585.2M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value EOLS
| FY Dec 2025 | $523.3M |
| FY Dec 2024 | $733.6M |
| FY Dec 2023 | $659.3M |
| FY Dec 2022 | $440.4M |
| FY Dec 2021 | $286.8M |
| Jun 2026 | $568.6M |
| Mar 2026 | $374.0M |
| Dec 2025 | $523.3M |
| Sep 2025 | $499.4M |
| Jun 2025 | $677.6M |
| Mar 2025 | $818.9M |
| Dec 2024 | $733.6M |
| Sep 2024 | $1.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield EOLS
| FY Dec 2025 | -10.6% |
| FY Dec 2024 | -2.8% |
| FY Dec 2023 | -5.7% |
| FY Dec 2022 | -20.5% |
| FY Dec 2021 | -9.3% |
| Jun 2026 | -4.0% |
| Mar 2026 | -15.0% |
| Dec 2025 | -10.6% |
| Sep 2025 | -13.3% |
| Jun 2025 | -7.3% |
| Mar 2025 | -3.2% |
| Dec 2024 | -2.8% |
| Sep 2024 | -2.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing EOLS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $297.2M | $266.3M | $202.1M | $148.6M |
| Gross profit | $197.1M | $182.3M | $137.6M | $89.8M |
| Operating income | -$32.7M | -$34.4M | -$49.2M | -$65.3M |
| Net income | -$51.6M | -$50.4M | -$61.7M | -$74.4M |
| EPS (diluted) | -0.80 | -0.81 | -1.08 | -1.33 |
| Operating cash flow | -$42.3M | -$18.0M | -$34.0M | -$84.9M |
| Cash | $53.8M | $87.0M | $62.8M | $53.9M |
| Long-term debt | $146.1M | $121.5M | $120.4M | $71.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
EOLS Stock Sonar score 6/7 axes
Find similar shapesCompareEOLS ranks highest on profitability (75th percentile) and financial health (68th), and lowest on insider conviction (18th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EOLS filings, in plain words
Are Evolus insiders buying or selling EOLS?
In the 180 days to 2026-10-28, Evolus insiders were net sellers, a net $950.0K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of EOLS?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $950.0K of stock; the latest, by DAVID MOATAZEDI, was filed 2026-09-02.
Read the full summary
In the 180 days to 2026-10-28, Evolus insiders were net sellers of EOLS, a net $950.0K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $950.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
